GLMD
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. (GLMD) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 39.8, with 0/3 trend checks passing.
GLMD with MA50 and MA200
Key levels & signals
Galmed Pharmaceuticals Ltd. (GLMD) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.51, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 14.2% and below the 200-day moving average by 37.5%.
GLMD currently has an RSI reading of 39.8, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.
For traders reviewing GLMD next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Learn the indicators behind this page
More stock opportunities
Common questions about GLMD
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.